Related Experiment Video
Updated: Mar 26, 2026
10:59
Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
Published on: February 7, 2025
1.9K
IgG Glycome in Colorectal Cancer
Frano Vučković1, Evropi Theodoratou2, Kujtim Thaçi1
1Genos Glycoscience Research Laboratory, Zagreb, Croatia.
Summary
Colorectal cancer alters IgG glycosylation, impacting immune response. Glycan analysis improved cancer prediction, highlighting its potential for personalized treatment strategies.
Area of Science:
- Immunology
- Glycobiology
- Oncology
Background:
- Alternative glycosylation of immunoglobulin G (IgG) significantly affects cancer immunosurveillance.
- Previous studies faced technological limitations in analyzing individual variations in IgG glycosylation dynamics in colorectal cancer.
Purpose of the Study:
- To investigate the impact of individual variations and dynamic changes in IgG glycosylation on colorectal cancer.
- To assess the potential of IgG glycome composition as a biomarker for colorectal cancer detection and prognosis.
Main Methods:
- Utilized high-throughput UPLC technology for IgG glycosylation analysis in 760 colorectal cancer patients and 538 controls.
- Employed regularized logistic regression to build a predictive model, evaluated using 10-cross validation.
- Analyzed IgG glycome composition in plasma samples from patients before initial diagnosis and after surgery.
Main Results:
- Colorectal cancer is associated with decreased IgG galactosylation and sialylation, and increased core-fucosylation of neutral glycans.
- The addition of glycan variables significantly improved the discriminative power of a predictive model (AUC = 0.755) compared to age and sex alone (AUC = 0.499).
- No significant glycan differences were observed in samples collected before initial diagnosis.
Conclusions:
- Individual variations in IgG glycosylation are functionally relevant for tumor immunosurveillance and therapeutic efficacy of monoclonal antibodies (mAbs).
- IgG glycosylation patterns may be important for predicting disease course and guiding therapy choices in colorectal cancer.
- Further detailed studies on IgG glycosylation in colorectal cancer are warranted.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
608
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
608
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
659
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
659
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
747
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
747
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
616
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
616
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
863
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
863
01:17Drugs for Treatment of Diarrhea-Predominant IBS
855
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
855